The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology
Open accessAbstract
A new diagnostic marker for urothelial carcinoma (UC) is needed to avoid painful cystoscopy during the initial diagnosis and follow‐up period. However, the current urine markers are useless because of the low sensitivities and specificities for UC detection. MiR‐96 and miR‐183 were differentially upregulated microRNA in our previous microRNA screening for UC. The expression levels of miR‐96 and miR‐183 in the urine samples were significantly higher in 100 UC than in healthy controls (miR‐96, P = 0.0059; and miR‐183, P = 0.0044). The receiver‐operating characteristic curve analyses demonstrated that each microRNA had good sensitivity and specificity for distinguishing UC patients from non‐UC patients (miR‐96, 71.0% and 89.2%; and miR‐183, 74.0% and 77.3%). Our cohort included 78 UC patients who had undergone urinary cytology. MiR‐96 was positively detected in 27 of 44 patients who had had a “negative” urinary cytology diagnosis. We combined the miR‐96 detection data with the urinary cytology data, and diagnosed 61 of 78 cases as UC; sensitivity rose from 43.6% to 78.2%. We found significant stepwise increases in miR‐96 and miR‐183 expression with advancing tumor grade (miR‐96, P = 0.0057; and miR‐183, P = 0.0036) and pathological stage (miR‐96, P = 0.0332; and miR‐183, P = 0.0117). The expression levels of the microRNA were significantly lower in urine collected after surgery (miR‐96, P = 0.0241; and miR‐183, P = 0.0045). In conclusion, miR‐96 and miR‐183 in urine are promising tumor markers for UC. In particular, miR‐96 may be a good diagnostic marker in combination with urinary cytology. (Cancer Sci 2011; 102: 522–529)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Cited by
microRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
Zhu, H., & Leung, S. W. (2015) · Diabetologia · doi:10.1007/s00125-015-3510-2 · Cited by 271
Metadata
- Authors
- Yamada, Y., Enokida, H., Kojima, S., Kawakami, K., Chiyomaru, T., Tatarano, S., Yoshino, H., Kawahara, K., Nishiyama, K., Seki, N., & Nakagawa, M.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2010-12-19
- Volume
- 102
- Issue
- 3
- Pages
- 522-529
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2109431382
- Cited by
- 215
- References
- 1
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. https://app.cochat.ai/papers/10.1111/j.1349-7006.2010.01816.x
- The paper
- Yamada, Y., Enokida, H., Kojima, S., Kawakami, K., Chiyomaru, T., Tatarano, S., Yoshino, H., Kawahara, K., Nishiyama, K., Seki, N., & Nakagawa, M. (2011). MiR‐96 and miR‐183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Science. https://doi.org/10.1111/j.1349-7006.2010.01816.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.